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Combined prolactin (PRL) and growth hormone (GH) secretion by a single pituitary tumor
can occur in approximately 5% of cases. However, in all previously reported patients,
combined secretion of both hormones was present at the time of diagnosis. Here we
describe a patient initially diagnosed with a pure prolactin-secreting microadenoma, who
experienced the progressive apparition of symptomatic autonomous GH secretion while
on intermittent long term dopamine agonist therapy. She was operated on, and immuno-
histochemical analysis of tumor tissue conﬁrmed the diagnosis of pituitary adenoma with
uniform co-staining of all cells for both GH and PRL. This patient represents the ﬁrst doc-
umented occurrence of asynchronous development of combined GH and PRL secretion
in a pituitary adenoma. Although pathogenic mechanisms implicated remain largely spec-
ulative, it emphasizes the need for long term hormonal follow up of patients harboring
prolactinomas.
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INTRODUCTION
Approximately 10% of all clinically overt intracranial neoplasms
arise from the pituitary gland and at autopsy, if histological exam-
ination of unselected autopsy material is to be believed, adenomas
are present in as many as one in ﬁve cases (Levy and Lightman,
1993). Prolactin-secreting adenomas are the most common of
them, representing about 40% of adenomas (Mindermann and
Wilson, 1994). Prevalence has classically been estimated at 6–10
per 100,000 inhabitants, but more recent data suggest it could be
as high as 62 per 100,000 inhabitants (Daly et al., 2006). Early diag-
nosis of mixed adenomas is rendered difﬁcult by the fact that they
generally present with signs or symptoms that can be related to
overproduction of a single hormone. Clinical diagnosis of com-
bined anterior pituitary hormone excess is thus a rare instance,
and these adenomas are mostly identiﬁed after neurosurgery, at
the time of pathological diagnosis.
The most frequent combination of pituitary hormone excess
associates growth hormone (GH) and prolactin (PRL); the combi-
nation of GH, PRL, and the alpha subunit (α-SU) of the glycopro-
tein hormones is also possible, whereas other hormone combina-
tions within a single tumor are extremely rare (Kovacs et al., 1998;
Ma et al., 2002). Ultrastructural and immune electronmicroscopic
data allow to classify bi-hormonal or pluri-hormonal adenomas
in three separate classes: monomorphous, bimorphous, and pluri-
morphous tumors. Monomorphous adenomas consist of a single
cell type with synthesis of two or more hormones in the same
cell. Bimorphous and plurimorphous adenomas are composed
of two or more cell types, and each hormone is produced by a
different cell population. However, overlaps may exist, and some
tumors can consist in a mix of cells, some of them producing only
one hormone and others producing two or more hormones. In
some adenomas, one cell type can predominate; in others, various
areas contain groups of similar cells, or a gradual transforma-
tion seems to exist between the cell types. Despite these overlaps,
the classiﬁcation of tumors into monomorphous, bimorphous,
and plurimorphous types for diagnostic purposes retains its value
and remains a useful practical tool (Kovacs et al., 1998). In this
paper, we describe a patient who presented initially with a pure
PRL secreting pituitary adenoma, and who secondarily developed
co-secretion of GH with time.
CASE REPORT
Here we present the case of female patient who delivered her ﬁrst
child in July 1996 at the age of 31 years, after spontaneous con-
ception and an uneventful pregnancy. She did not breast feed her
baby, and was seen again in May 1997, where she complained
of persistent secondary amenorrhea and intermittent galactor-
rhea of 10months’ duration. No speciﬁc investigations were per-
formed at the time, and substitutive treatment with Estradiol and
Norgestrel (Cyclacur®) was initiated by her treating gynecologist.
This resulted in regular menstruations, but the treatment was
stopped by the patient in September 1997 because of a desire
of pregnancy, allowing to conﬁrm the persistence of secondary
amenorrhea.
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She was otherwise in good general health, had no particu-
lar complaint and was on no medication, only reporting having
lost 10 kg after her ﬁrst pregnancy. On physical exam, she was a
healthy appearing young woman weighing 51 kg for 162 cm, the
only positive ﬁnding being the presence of bilateral galactorrhea
on stimulation. A pregnancy test was negative, and investigation
of anterior pituitary function disclosed the following baseline hor-
mone levels (November 1997): LH 1.6 U/l (N : 2–12), FSH 4.8 U/l
(N : 4–12), oestradiol 0.2 nmol/l (N : 0.14–0.34); PRL 42μg/l (N :
3.4–24.1); TSH 0.79mU/l (N : 0.2–3.5), free T4 15 pmol/l (N : 8–
22). GH and IGF-1 levels were reportedly within normal limits at
the time. The patient refused to undergo a pituitary MRI because
of claustrophobia, and a head CT scan disclosed the presence of a
microadenoma (7× 4mm) in the left lobe of the pituitary gland.
The diagnosis of microprolactinoma was retained, based on
the good correlation between the relatively small size of the ade-
noma and the moderate, albeit symptomatic, elevation of pro-
lactin levels. Thus, dopamine agonist therapy with Quinagolide
(Norprolac® 75mg/day)was initiated in January 1998.A fewweeks
later, the patient became pregnant, treatment was stopped, and an
uneventful pregnancy resulted in the delivery of a normal sec-
ond child in October 1998. The patient was able to breast feed
her baby. At the follow up visit in March 1999, the patient was
still amenorrheic and she had persistent bilateral galactorrhea on
stimulation. Her baseline prolactin level was 66 μg/l (N : 2–19),
and IGF-1 was normal at 342μg/l (N : 98–442) in July 1999. A
repeat head CT scan conﬁrmed the presence of a stable microade-
noma. She then refused to take any medication, and also refused
to take oral contraception.
Over the course of the following years, her baseline prolactin
levels increased slowly but steadily, reaching 92 μg/l (N : 2–19) in
2002. Because of the risk of osteoporosis carried by long term
amenorrhea, the patient then agreed upon taking dopamine ago-
nist therapy and was started on oral Cabergoline (Dostinex®
0.5mg/week) in June 2002. As anticipated, her serum prolactin
levels declined, galactorrhea disappeared and by October 2002,
regular ovulatory cycles had resumed. However, she experienced a
minor depression on cabergoline that required transient treatment
(August 2002–June 2003) with the selective serotonin re-uptake
inhibitor nefazodone (Nefadar®). In May 2004, recurrence of
amenorrhea under treatment motivated a repeat head CT scan
which disclosed a small decrease in size of the adenoma. At the
time, serum PRL levels were stable at 57μg/l and notably did not
exhibit any signiﬁcant change despite the transient treatment with
a selective serotonin re-uptake inhibitor that had occurred a few
months before. Cabergoline was increased to 0.75mg/week, with
return of the menses. The ﬁrst MRI was obtained in June 2005,
showing an oval hypointense (T1) nodule in the left lobe of the
pituitary gland,measuring 5mm by 3mm (i.e., smaller than on all
previous imaging studies). In December of that year, the patient
decided to stop taking cabergoline. She became amenorrheic again
shortly thereafter, with Prolactin levels rising to 110 μg/l in August
2006, prompting re-introduction of the treatment. IGF-1 levels at
that time were evaluated in a novel assay because of a change in
the methodology used at our hospital and amounted to 356μg/l
(N : 106–276, see Figure 1).
Once again, therapywas stopped by the patient inApril 2007, an
interruption that was followed by another episode of amenorrhea
FIGURE 1 | Summary of the evolution of prolactin and IGF-1 levels over
time, and with respect to the various treatments administered between
August 2006 and July 2010.This graph illustrates the sudden rise in IGF-1
levels (squares) between 2006 and 2007, as well as the good response to
long-acting octreotide therapy and the resolution of both IGF-1 and prolactin
(triangles) hypersecretion after trans-sphenoidal surgery.
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FIGURE 2 | Evolution of the adenoma on long-acting octreotide
therapy (A,B) and result of trans-sphenoidal surgery [(C), i.e.,
17months after surgery]. (A) MRI November 2007 (Coronal T1 after
gadolinium injection): oval hypointense nodule in the left lobe of pituitary
gland, measuring 10mm on 6mm. No invasion of the cavernous sinus.
Small cyst at the root of the pituitary stalk. (B) MRI March 2009 (Coronal T1
after gadolinium injection): in comparison to November 2007, small
decrease (under long-acting octreotide therapy) of left microadenoma, still
in contact with the left cavernous sinus (without any sign of invasion).
(C) MRI August 2010 (Coronal T1 after gadolinium injection): the adenoma
has been removed leaving only minor scar tissue in the left anterior pituitary
lobe. The small cyst has gradually disappeared.
accompanied by intermittent galactorrhea. At her next yearly fol-
low up visit in November 2007, she mentioned spontaneously an
increase in size of her ﬁngers. On speciﬁc questioning, she also
reported disseminated arthralgias, and symptoms suggestive of
carpal tunnel syndrome. Baseline hormone work up at the time
was as follows: PRL was stable at 51μg/l (N : 4–29), but IGF-1 was
signiﬁcantly higher than a few months before, at 480 μg/l (N : 98–
261). A repeat pituitary MRI was therefore obtained in November
2007 (see Figure 2A) disclosing the existence of a mixed solid
and cystic nodule in the left lobe of the anterior pituitary gland,
measuring 6 by 10mm. This nodule was larger than on previous
imaging studies, and was located in contact with the left cavernous
sinus without sign of invasion. This MRI exam also showed a sec-
ond lesion localized at the root of the pituitary stalk, measuring
3 by 3mm, corresponding to a small cyst. A GH suppression test
with oral glucose was then performed, conﬁrming autonomous
GH secretion (Table 1).
Because of the apparition of GH hypersecretion, long-acting
octreotide therapy (Sandostatin LAR® 10mg a month, increased
to 20mg after 3months) was started in January 2008, with good
resolution of symptoms. IGF-1 levels, which were still elevated at
473μg/l in April 2008, decreased within a few months to reach a
nadir of 335 μg/l (N : 98–261) in August 2008. At that time, IGF-
BP3 levels were within normal limits at 5.2mg/l (N : 3.3–6–6)
and prolactin was stable at 37 μg/l (N : 4–29) on oral Caber-
goline (Dostinex® 0.5mg/week). A repeat pituitary MRI after
6months (not shown) disclosed no change. The dose of long-
acting octreotide therapy was increased to 30mg a month,without
complete normalization of IGF-1 values (350μg/l, N : 98–261)
in October 2008. A repeat pituitary MRI in March 2009 showed
a small decrease of the microadenoma, which was still in con-
tact with the left cavernous sinus. The cystic lesion at the root of
pituitary stalk was stable (see Figure 2B).
Resection of this microadenoma was performed by trans-
phenoidal approach in March 2009 (i.e., after 13months of
long-acting octreotide treatment). Preoperative IGF-1 and IGF-
BP3 levels were 275μg/l (N : 98–261) and 3.8mg/l (N : 3.3–6–6),
respectively. Prolactin was normal at 5 μg/l (N : 4–29). Peri-
operative course was uneventful. Pathological exam of tumor tis-
sue conﬁrmed the diagnosis of pituitary adenomawithmonomor-
phous staining for GH and PRL at immunohistochemistry (see
Figure 3). There was no expression of LH, FSH, TSH, ACTH, or
HCG by the tumor.
All therapy was withheld and at the 3-months follow up visit,
IGF-1 and IGF-BP3 levels were normal at 153μg/l (N : 98–261)
and 4.8mg/l (N : 3.3–6–6) respectively. Prolactin was also normal
at 11μg/l (N : 4–29), as was the remaining of anterior pituitary
function. Biological remission of the disease was conﬁrmed at
6months, and performance of a GH suppression test with oral
glucose showed a nadir GH level of 0.51 μg/l after 120min. The
control MRI realized in 2010 showed no residual tumor and the
small cyst had also disappeared (see Figure 2C). Blood hormone
levels were as follows (July 2010): PRL 16 μg/l (N : 4–29), IGF-1
120μg/l (N : 98–261), and IGF-BP3 3.8mg/l (N : 3.3–6–6).
DISCUSSION
Combined prolactin and GH secretion has been reported in 5% of
all pituitary tumors, an co-secretion is usually diagnosed simul-
taneously (Kasantikul and Shuangshoti, 1990). Mixed prolactin
and GH secreting pituitary adenomas are relatively common
because somatotrophs and lactotrophs share the common somato-
mammotroph progenitor lineage. Conversely, the occurrence of
a prolactinoma evolving into clinically and biochemically active
acromegaly seems to be a rare phenomenon. In a recent report,
Lania et al. (2010) describe secondary apparition of GH hyper-
secretion. However, in contrast to the patient described here, the
primary tumor in their reportwas an aggressive prolactinoma,sug-
gesting a different pathophysiological mechanism from the start.
In this context, older papers describing the occurrence of com-
bined elevations of GH and prolactin do not allow to differentiate
between concomitant or sequential development of the individ-
ual hypersecretion syndromes (Tournaire et al., 1985; Goldman
and Klinges, 1989; Pagesy et al., 1991). Moreover, it should also be
reminded that elevated prolactin levels in the context of a soma-
totroph adenoma can also result from desinhibition of lactotroph
cells by pituitary stalk compression.
In contrast to these previous reports, the patient discussed here
is remarkable in the sense that symptoms of GH excess appeared
progressively, several years after the diagnosis of microprolactin-
oma. Very importantly, clinical symptoms were well correlated
with the biological ﬁndings. Indeed, an elevation of IGF-1 levels
was not observed before 2006, and the ﬁrst spontaneous com-
plaint suggestive of GH excess was recorded in 2007. The fact
that once documented, these elevated IGF-1 levels continued to
increase steadily on further testing, together with the good cor-
relation with clinical symptoms, argues very much in favor of
secondary apparition of GH hypersecretion and against an arti-
fact related to the change in the IGF-1 assay that occurred in 2005.
This is further conﬁrmedby the clearly abnormal results of the oral
glucose suppression test, conﬁrming the abnormal GH secretion.
Interestingly, this change in phenotype from a pure prolactin-
secreting adenoma into a mixed somato-lactotroph adenoma was
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Table 1 | Results of the oral glucose tolerance tests (=oGTT) performed before and after successful trans-sphenoidal surgery, demonstrating the
lack of inhibition of GH before surgery, and the inhibition of GH levels to a nadir of 0.51ng/mL followed by physiological rebound at 180min
after surgery.
Oral glucose tolerance test (75g) before and after surgery
Time(min) t000 t030 t060 t090 t120 t180
GH value (μg/l)
Before surgery (Nov. 2007) 8.21 7.08 6.32 6.76 7.78 8.99
After surgery (Sept. 2009) 3.01 NA NA 0.54 0.51 15.8
NA, non-available.
FIGURE 3 | Histopathological exam of resected tissue. (A)
Hematoxylin-eosin staining (Magniﬁcation ×10): pituitary adenoma
composed of round to polygonal cells with abundant eosinophilic or
granular cytoplasm. The cells are arranged in solid nests or trabeculae.
(B) Immunohistochemical analysis (Magniﬁcation ×10) with an anti-GH
antibody (polyclonal), demonstrating monomorphous expression of GH
in the majority of cells. (C) Immunohistochemical analysis
(Magniﬁcation ×10) with an anti-PRL antibody (polyclonal),
demonstrating monomorphous expression of PRL in the majority of
cells.
accompanied by signiﬁcant growth of the known pituitary tumor,
after several years of stability in size. This unfortunate evolution, in
parallel with the change in the secretory proﬁle of the tumor, could
therefore be interpreted as a sign of de-differentiation. Indeed,
hormone-speciﬁc anterior pituicytes are embryologically derived
from a pluripotent precursor. The process of anterior pituitary
cell development and differentiation arises as a consequence of
concerted spatio-temporal expression or repression of a series of
transcription factors to produce fully differentiated cells of the
various lineages (Melmed, 2003). In this differentiation process,
prolactin-expressing cells are just one step downstream from cells
expressing both GH and prolactin.
At that point of the clinical evolution, and regardless of the
pathogenic mechanisms implicated, the indication for surgical
resection of the adenoma was retained. Given the close vicinity
of the cavernous sinus, pre-treatment with a long-acting somato-
statin analog was initiated in order to increase the chance of
curative trans-sphenoidal surgery (Ferone et al., 2000). This option
proved successful since medical treatment induced a signiﬁcant
reduction of the tumor size, ultimately allowing radiologically
complete resection of all tumor tissue. Immunohistochemical
exam of the removed tumor disclosed a pituitary adenoma with
uniformco-staining for bothGHandPRL,conﬁrming thehypoth-
esis of an evolution into a mixed somato-mammotroph pituitary
adenoma.
The cytogenesis of pituitary adenomas that consist of two dif-
ferent cell populations is not known and remains to be elucidated
(Kovacs et al., 1998), although different hypotheses have been
proposed. Most, if not all, of these adenomas are monoclonal,
as demonstrated by X-inactivation studies (Herman et al., 1990;
Ma et al., 2002). Moreover, at the end of the eighties, an activating
mutation of the α-SU of G proteins was identiﬁed in somatotroph
cells of up to 40% of sporadic GH-secreting pituitary adenomas
in Caucasians (Landis et al., 1990; Levy and Lightman, 1993).
The resulting oncogene, gsp, was thought to induce tumorige-
nesis by virtue of persistent activation of adenylyl cyclase, with
subsequent GH hypersecretion (Landis et al., 1989; Eugster and
Pescovitz, 1999). This report constitutes the demonstration that
speciﬁc molecular abnormalities may form the basis of pituitary
adenoma formation and hormone hypersecretion, at least in some
speciﬁc cases.
Alternatively, it may be hypothesized that such mixed pitu-
itary adenomas are not monoclonal, and that the insult that
causes the neoplastic transformation may affect two different cell
types. It is also conceivable that some pituitary tumors origi-
nate in an uncommitted stem cell which, because of unknown
factors, can differentiate into two separate cell types. Such multi-
directional differentiation could explain the development of some
pluri-hormonal tumors (Kovacs et al., 1998).
Another hypothesis would be that one cell type can “transdif-
ferentiate” to another cell type as a result of subsequent mutations
during tumor progression. Such phenomenon involves reversible
transformation of one cell type to another by phenotypic switches,
without cell division (Senovilla et al., 2004). It takes place in a few
pituitary cell types under physiological conditions. This concept
of transdifferentiation was for example introduced to explain the
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existence of “somato-mammotrope” cells, a cell type that stores
and secretes both GH and PRL which is generated by the con-
version of somatotropes into mammotrophs during situations
demanding large amounts of PRL such as lactation (Frawley and
Boockfor, 1991). Transdifferentiation has also been shown in the
pituitaries of rats made hypothyroid by chemical thyroidectomy
(Horvath et al., 1990), and reversible phenotypic switching of GH
and PRL gene expression has long been reported in experimental
rat pituitary tumor cells (Ivarie and Morris, 1983; Melmed, 2003).
Thus, pathogenic mechanisms of pituitary adenoma formation
remain poorly understood, especially in sporadic occurrences such
as in the patient discussed here. It should also be noted that this
change in the phenotype of the tumor was observed while the
patient was on long term dopamine agonist treatment, but also
that therapy had been discontinued spontaneously by the patient
on several occasions over the years. One could therefore speculate
that poor adherence to dopamine agonist therapy may have played
a role in this rather unusual evolution, by allowing emergence of
a less differentiated adenomatous cell lineage.
In conclusion, we believe that this patient represents the ﬁrst
deﬁnitive documented evidence of the secondary apparition of
GH autonomous secretion within a known microprolactinoma.
This phenotypic change of the adenoma was accompanied by
a change in its growth potential, suggesting some degree of de-
differentiation. Complements of investigations by immunohisto-
chemistry,DNA analyses, and clonality of tumor specimens would
have been interesting to obtain, in order to understand what was
responsible for this change. Pathogenic mechanisms implicated
in this rather unusual evolution for a microprolactinoma remain
largely unclear, and the potential role played by poor therapeutic
adherence is only speculative. However and regardless of the path-
ogenic mechanisms implicated, the clinical course of this unusual
patient emphasizes the need for long term hormonal follow up of
all pituitary adenomas.
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